CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics; and CB-0406, which is in Phase I clinical trial for the inflammation disease/condition. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
IPO Year:
Exchange: NASDAQ
Website: cymabay.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2024 | Outperform → Mkt Perform | Raymond James | |
| 8/14/2023 | $18.00 | Buy | UBS |
| 8/11/2023 | $20.00 | Buy | Guggenheim |
| 4/5/2023 | Outperform | William Blair | |
| 3/9/2023 | $15.00 | Buy | BTIG Research |
| 4/11/2022 | $9.00 | Overweight | Cantor Fitzgerald |
| 11/11/2021 | $12.00 → $14.00 | Strong Buy | Raymond James |
| 8/3/2021 | $13.00 → $12.00 | Buy | HC Wainwright & Co. |
Gilead Sciences Inc’s (NASDAQ:GILD) executive revealed the company’s plans to increase its production of cell therapy cancer treatments fourfold by 2026. In an interview with Reuters, Cindy Perettie, the executive vice president of Gilead’s Kite cell therapy unit, said the advancements stem from significant enhancements in Gilead’s manufacturing processes. Related: Gilead’s Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of “Risks Of Secondary Cancer’ Perettie noted that these improvements have increased the annual production of patient treatments from 6,000 to 10,000 within the past year. Gilead’s focus on cell therapies, particularly its chimeric ant
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here’s the latest list of major overbought players in this sector. Molina Healthcare, Inc. (NYSE:MOH) On March 6, Barclays analyst Andrew Mok initiated coverage o
CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the Marketing Authorization Application (MAA) for seladelpar, for the treatment of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid), has been validated and will now be reviewed by the European Medicines Agency (EMA). Seladelpar is an investigational, potent, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist or delpar, in development for PBC treatment.
HC Wainwright & Co. analyst Ed Arce reiterates CymaBay Therapeutics (NASDAQ:CBAY) with a Neutral and maintains $32.5 price target.
CymaBay Therapeutics (NASDAQ:CBAY) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.31) by 12.9 percent. This is a 16.67 percent decrease over losses of $(0.30) per share from the same period last year.
Leerink Partners analyst Thomas Smith downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Outperform to Market Perform and announces $32.5 price target.
LifeSci Capital analyst Cory Jubinville downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Outperform to Market Perform.
Piper Sandler analyst Yasmeen Rahimi downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Overweight to Neutral and lowers the price target from $33 to $32.5.
Monday, Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for primary biliary cholangitis (PBC), including pruritus, complements Gilead’s existing liver portfolio. Baird writes that Gilead’s investment in seladelpar for liver disease appears to be a strategically sound move, especially compared to potential investments in oncology. The company’s focus on a space where it has demonstrated commercial success is seen as a positive step to restore confidence in its growth prospects. Despite the m
15-12G - CymaBay Therapeutics, Inc. (0001042074) (Filer)
EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)
EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)
EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)
EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)
EFFECT - CymaBay Therapeutics, Inc. (0001042074) (Filer)
S-8 POS - CymaBay Therapeutics, Inc. (0001042074) (Filer)
S-8 POS - CymaBay Therapeutics, Inc. (0001042074) (Filer)
S-8 POS - CymaBay Therapeutics, Inc. (0001042074) (Filer)
S-8 POS - CymaBay Therapeutics, Inc. (0001042074) (Filer)
4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)
4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)
4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)
4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)
4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)
4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)
4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)
4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)
4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)
4 - CymaBay Therapeutics, Inc. (0001042074) (Issuer)
Submission status for CYMABAY THERAPEUTICS INC's drug LIVDELZI (ORIG-1) with active ingredient SELADELPAR has changed to 'Approval' on 08/14/2024. Application Category: NDA, Application Number: 217899, Application Classification: Type 1 - New Molecular Entity
Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. U.S. FDA accepted seladelpar NDA for priority review, and seladelpar marketing applications were submitted to the EMA and MHRA for review in Europe and the U.K. Due to the pending transaction with Gilead, CymaBay will not be hosting a conference call to review the financial results for the fourth quarter ended December 31, 2023 or commenting on its financial guidance for the future quarters. NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing thera
NEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that it will host a conference call and live audio webcast on Tuesday, November 7, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2023 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 1-877-407-0784 from the U.S. and Canada, or 1-201-689-8560 internationally, Conference ID #13740701. To access the live and subsequently archived webcast of the conference call, go t
Primary composite endpoint at 12 months of serum alkaline phosphatase and bilirubin was met by 61.7% of patients treated with seladelpar 10 mg vs. 20.0% of placebo treated patients (p<0.0001) Normalization of alkaline phosphatase at 12 months was achieved by 25.0% of patients treated with seladelpar vs. 0% on placebo (p<0.0001) In patients having moderate-to-severe itch at baseline, the seladelpar treated group improved their pruritus at 6 months compared to those in the placebo group (p<0.005) Safety and tolerability were comparable between placebo and seladelpar groups and consistent with previous studies CymaBay will hold a conference call to discuss these results today at 8:00 a.m. ET N
NEWARK, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will host an investor call on Thursday, September 7 at 8:00 a.m. ET to share topline results from the Phase 3 pivotal RESPONSE study of seladelpar in patients with primary biliary cholangitis (PBC). To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13741034. To access the live and archived webcast of the conference call, go to the Investors section of t
Top-line data from RESPONSE Phase 3 study in PBC expected by end of September 2023 IDEAL clinical trial actively recruiting Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today corporate updates and financial results for the second quarter ended June 30, 2023. Sujal Shah, President and CEO of CymaBay, stated, "I'm incredibly proud of the progress our teams have made thus far this year as we march towards our key and exc
NEWARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today that it will host a conference call and live audio webcast on Thursday, August 10, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2023 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 877-308-2053 from the U.S. and Canada, or 212-231-2921 internationally, Conference ID # 22027740. To access the live and subsequently archived webcast of the confer
Harish Shantharam, proven leader in building financial organizations to prepare for successful commercialization, appointed as Chief Financial Officer Results from ENHANCE phase 3 global study of seladelpar in patients with PBC published in Hepatology Completed a public equity offering totaling net proceeds of $92.4 million Entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases, today announced corp
NEWARK, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, May 15, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2023 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 844-825-9789 from the U.S. and Canada, or 412-317-5180 internationally, Conference ID # 10178303. To access the live and subsequently archived webcast of the conference c
NEWARK, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended December 31, 2022. Sujal Shah, President and CEO of CymaBay, stated, "We are off to a fast start in 2023 after making significant progress in 2022 in our development program evaluating seladelpar for patients with primary biliary cholangitis (PBC). Since completing enrollment in RESPONSE, our global phase 3 registration study, in July 2022, we presented data at The Liver Me
NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 16, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2022 and to provide a business update. Conference Call DetailsTo access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID # 13736281. To access the live and subsequently archived webcast
Acquisition Reinforces Gilead's Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (NASDAQ:GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (NASDAQ:CBAY) for approximately $4.3 billion in total equity value. The addition of CymaBay's investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead's existing liver portfolio and aligns with its long-standing commitment to bringing transformational medicines to patients. "The acquisition of CymaBay brings us a potential best in disease therapy that
NEWARK, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the Marketing Authorization Application (MAA) for seladelpar, for the treatment of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid), has been validated and will now be reviewed by the European Medicines Agency (EMA). Seladelpar is an investigational, potent, selective peroxisome proliferator-activated receptor delta (PPARδ)
Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. U.S. FDA accepted seladelpar NDA for priority review, and seladelpar marketing applications were submitted to the EMA and MHRA for review in Europe and the U.K. Due to the pending transaction with Gilead, CymaBay will not be hosting a conference call to review the financial results for the fourth quarter ended December 31, 2023 or commenting on its financial guidance for the future quarters. NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing thera
- Seladelpar demonstrated normalization of liver biomarkers and significant reductions across three measures of patient-reported itch vs. placebo - NEWARK, Calif., Feb. 21, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that The New England Journal of Medicine (NEJM) has published detailed results from the RESPONSE Phase 3 trial evaluating seladelpar, an investigational agent, and the only potent, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist or delpar, being studied in adults with primary biliary cholangitis (PBC). Re
NEWARK, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to three employees on February 16, 2024 (the "Grant Date") in connection with the employees' commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualified stock options to purchase an aggregate of 99,000 shares of CymaBay common stock as inducements material to the employees entering into employment with CymaBay in accordance with Nasdaq Listing R
- FDA has granted Priority Review with a target PDUFA date of August 14 - NEWARK, Calif., Feb. 12, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for seladelpar, an investigational treatment for the management of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid. The FDA has granted priority review and set a Prescription
-- Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U.S. Approval in Third Quarter of 2024 -- -- Seladelpar Phase 3 Data Demonstrates a Best-in-Disease Profile for Second-Line PBC -- -- Acquisition Expands Gilead's Long-Standing Commitment to Patients with Liver Diseases -- Gilead Sciences, Inc. (NASDAQ:GILD) and CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay's investigational lead product candidate, seladelpar for the tre
NEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, February 7-8, in New York, NY, Raymond James & Associates' 45th Annual Institutional Investors Conference, March 4-6, in Orlando, Florida, and Leerink Partners Global Biopharma Conference, March 11-13, in Miami, Florida. Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceDate: Wednesday, February 7th, 2024Time: 1:00pm Eastern Time, Firesid
NEWARK, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to two employees on January 12, 2024 (the "Grant Date") in connection with the employees' commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualified stock options to purchase an aggregate of 52,000 shares of CymaBay common stock as inducements material to the employees entering into employment with CymaBay in accordance with Nasdaq Listing Rule
-- First clinical trial in PBC to show coordinate reductions of IL-31, bile acids and pruritus -- NEWARK, Calif., Jan. 3, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced the first published findings demonstrating the impact of seladelpar on serum interleukin-31 (IL-31) levels and its correlation with pruritus improvement in people with primary biliary cholangitis (PBC). Seladelpar is a first-in-class oral, selective PPARδ agonist being investigated for the treatment of patients with PBC. The latest findings from a post-hoc analysis of the Phase 3 ENHA
Raymond James downgraded CymaBay Therapeutics from Outperform to Mkt Perform
UBS initiated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $18.00
Guggenheim initiated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $20.00
William Blair initiated coverage of CymaBay Therapeutics with a rating of Outperform
BTIG Research initiated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $15.00
Cantor Fitzgerald resumed coverage of CymaBay Therapeutics with a rating of Overweight and set a new price target of $9.00
Raymond James reiterated coverage of CymaBay Therapeutics with a rating of Strong Buy and set a new price target of $14.00 from $12.00 previously
HC Wainwright & Co. reiterated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $12.00 from $13.00 previously
JonesTrading initiated coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $8.00
Piper Sandler resumed coverage of CymaBay Therapeutics with a rating of Buy and set a new price target of $12.00
SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)
SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)
SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)
SC 13G - CymaBay Therapeutics, Inc. (0001042074) (Subject)
SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)
SC 13G - CymaBay Therapeutics, Inc. (0001042074) (Subject)
SC 13G - CymaBay Therapeutics, Inc. (0001042074) (Subject)
SC 13G - CymaBay Therapeutics, Inc. (0001042074) (Subject)
SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)
SC 13G/A - CymaBay Therapeutics, Inc. (0001042074) (Subject)
NEWARK, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Charles McWherter as President of Research and Development. "We are excited to announce the promotion of Chuck to President of Research and Development, in addition to his continuing role as Chief Scientific Officer. Chuck joined CymaBay in 2007 and has served as Chief Scientific Officer since 2013. In this role he has been instrumental in the development of seladelpar. Chuck's extensive experience in the pharmaceutical industry
NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Éric Lefebvre to its Board of Directors. "We are excited to be welcoming Éric to the Board. Éric's extensive experience in the pharmaceutical industry as an executive focused on clinical development, medical affairs, business development and life-cycle strategy and more than 10 years of experience developing drugs in liver disease indications make him a perfect addition to our Board. We look forward to Éric helping guide us thr
NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of biopharma veteran Thomas Wiggans and commercial leader Janet Dorling to its Board of Directors. Concurrently with these appointments, CymaBay announced that Paul F. Truex has resigned from the Board of Directors effective as of April 1, 2021 to focus on his new role as Chief Executive Officer of LQT Therapeutics. “We are truly excited to be welcoming Tom and Janet to the Board. Tom’s experience leading biopharma companies, such a